Giusti M, Guido R, Valenti S, Giordano G
DiSEM, Cattedra di Endocrinologia, University of Genova, Italy.
J Endocrinol Invest. 1999 Jan;22(1):6-11. doi: 10.1007/BF03345471.
Leptin may be a possible trigger for puberty. In normal males, it has been shown that leptin increases from the pre-pubertal to the early pubertal stage, and then declines in the late pubertal stage. We examined leptin levels in six male adolescents (mean age 16.3+/-0.6 yr; range 14.2-17.6 yr) with delayed puberty (constitutional delay of puberty no.=2; idiopathic hypogonadotropic hypogonadism no.=4) during 120 days of subcutaneous pulsatile GnRH administration. A group of subjects in pre-puberty (no.=11), early-puberty (n=10) and mid-puberty (no.=7) were evaluated as controls. Morning blood samples were taken for determination of leptin, testosterone, LH and FSH levels. In delayed puberty subjects blood samples were taken every 30 days after the start of GnRH administration. At each examination BMI and testicular volume were evaluated. A follow-up examination was performed in the 6 patients 1.3-7.5 yr after the end of the 120 days of GnRH therapy. At baseline evaluation in delayed puberty mean leptin levels were 11.3+/-2.0 microg/l (median 11.3 microg/l; range 4.7-17.3 microg/l) and were higher than those found in pre-puberty (p=0.04) and mid-puberty (p=0.001). During GnRH administration there was no change in BMI and leptin levels but there was an increase in gonadotrophin levels, testosterone and testicular volume. One hundred and twenty days after, mean serum leptin were 10.1+/-2.1 microg/l (median 9.1 microg/l; range 3.4-16.8 microg/l). At the end of the study, leptin levels were higher in delayed puberty than in mid-puberty (p=0.002). At the follow-up examination leptin levels were 4.3+/-1.3 microg/l (median 3.4 microg/l; range 1.4-9.1 microg/l) (p=0.03 vs end of 120 days GnRH therapy) while testosterone and BMI were not changed. In conclusion 120-day pulsatile GnRH administration induced in males with delayed puberty physiological-like pubertal changes but not the decline in leptin levels reported during the progression of puberty. Therefore, in males with delayed puberty an impairment in the phenomenon of leptin decline associated with progression of puberty could be suggested. However after retrospective diagnosis of pubertal delay and long-term therapy in subjects with idiopathic hypogonadotropic hypogonadism leptin levels declined. These data seem to indicate that time more than increase in testosterone levels and testicular volume is the determinant of leptin decline at puberty.
瘦素可能是青春期启动的一个潜在触发因素。在正常男性中,已证实瘦素水平从青春期前到青春期早期升高,然后在青春期后期下降。我们检测了6名青春期发育延迟男性青少年(平均年龄16.3±0.6岁;范围14.2 - 17.6岁)(体质性青春期延迟2例;特发性低促性腺激素性性腺功能减退4例)在皮下脉冲式注射促性腺激素释放激素(GnRH)120天期间的瘦素水平。选取一组青春期前(n = 11)、青春期早期(n = 10)和青春期中期(n = 7)的受试者作为对照。于清晨采集血样以测定瘦素、睾酮、促黄体生成素(LH)和促卵泡生成素(FSH)水平。对于青春期发育延迟的受试者,在开始GnRH治疗后每30天采集血样。每次检查时评估体重指数(BMI)和睾丸体积。在GnRH治疗120天结束后1.3 - 7.5年,对这6例患者进行了随访检查。在青春期发育延迟的基线评估中,平均瘦素水平为11.3±2.0μg/L(中位数11.3μg/L;范围4.7 - 17.3μg/L),高于青春期前(p = 0.04)和青春期中期(p = 0.001)的水平。在GnRH治疗期间,BMI和瘦素水平无变化,但促性腺激素水平、睾酮和睾丸体积有所增加。120天后,平均血清瘦素为10.1±2.1μg/L(中位数9.1μg/L;范围3.4 - 16.8μg/L)。在研究结束时,青春期发育延迟者的瘦素水平高于青春期中期(p = 0.002)。在随访检查时,瘦素水平为4.3±1.3μg/L(中位数3.4μg/L;范围1.4 - 9.1μg/L)(与GnRH治疗120天结束时相比,p = 0.03),而睾酮和BMI未改变。总之,120天脉冲式GnRH给药可使青春期发育延迟的男性出现类似生理性的青春期变化,但未出现青春期进展过程中报道的瘦素水平下降。因此,对于青春期发育延迟的男性,可能提示其存在与青春期进展相关的瘦素下降现象受损。然而,在对特发性低促性腺激素性性腺功能减退患者进行青春期延迟的回顾性诊断和长期治疗后,瘦素水平下降。这些数据似乎表明,时间而非睾酮水平和睾丸体积的增加才是青春期瘦素下降的决定因素。